生物制剂治疗特应性皮炎的新进展
Research progress on the treatment of biologicals on atopic dermatitis
陈倩茹 1沈晓峰 1康晓静2
作者信息
- 1. 830000 乌鲁木齐,新疆医科大学第五附属医院皮肤科
- 2. 新疆维吾尔自治区人民医院皮肤性病科,新疆皮肤性病临床医学研究中心,新疆皮肤病研究重点实验室
- 折叠
摘要
特应性皮炎(AD)是一种慢性炎症性皮肤病,以反复发作的慢性湿疹样皮炎为主要表现,患者常伴有其他特应性疾病或具有特应性疾病家族史,累及人群年龄分布广泛,病程长,严重影响患者生活质量.既往AD的系统治疗以抗组胺药、糖皮质激素、免疫抑制剂等为主,由于不良反应多,故在药物选择及维持治疗方面存在一定的局限性.生物制剂作为一种新型治疗药物极大地改善了免疫相关性疾病的治疗及预后,目前对于中重度AD患者,应用生物制剂治疗的相关研究正在积极开展.兹对AD治疗相关的生物制剂及其研究现状做一综述.
Abstract
Atopic dermatitis(AD)is a chronic inflammatory skin disease characterized by recurrent chronic eczematoid dermatitis.Patients are often accompanied by other atopic diseases or have a family history of atopic diseases.The affected population spans a wide age range,and the disease course is prolonged,significantly impacting patients'quality of life.In the past,the systemic treatments for AD have mainly included antihistamines,glucocorticoids,immunosuppressive agents,etc.However,due to many adverse reactions,there are some limitations in drug selection and maintenance therapy.As a new therapeutic drug,biological agents have greatly improved the treatment and prognosis of immune-related diseases.Currently,active research is underway regarding the use of biological agents in the treatment of moderate to severe atopic dermatitis.This article reviews the biological agents related to AD treatment and their research status.
关键词
皮炎,特应性/生物制剂/单克隆抗体Key words
Dermatitis,atopic/Biologicals/Monoclonal antibody引用本文复制引用
基金项目
新疆维吾尔自治区重点研发计划(2021B03001-1)
出版年
2024
NETL
NSTL
万方数据